Tirzepatide and prevention of chronic kidney disease
Clinical Kidney Journal · 04.05.2023 · 16 (5) · 797-808
DOI: 10.1093/ckj/sfac274 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 23.12.2022. Verfasst von Catalina Bosch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Universitario CEMIC, Buenos Aires, Argentina. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FEDER, PERSTIGAN, ISCIII-RETIC.
Abstract (Originalsprache)
Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors. In recent clinical trials in persons with obesity or overweight with associated conditions, tirzepatide decreased body weight and other cardiorenal risk factors (blood pressure, low-density lipoprotein cholesterol, glycated hemoglobin and albuminuria). Moreover, in a post hoc analysis of the SURPASS-4 randomized clinical trial, tirzepatide decreased albuminuria and total estimated glomerular filtration rate (eGFR) slopes and nearly halved the risk of a pre-specified composite kidney endpoint (eGFR decline ≥40%, renal death, kidney failure or new-onset macroalbuminuria) in participants with T2DM and high cardiovascular risk when compared with insulin glargine. Similar to other kidney-protective drugs, tirzepatide, alone or combined with sodium-glucose co-transporter 2 inhibitors, caused an early dip in eGFR. Moreover, tirzepatide also decreased eGFR slopes in participants with eGFR >60 mL/min/1.73 m2 or with normoalbuminuria. We now review the potential kidney health implications of tirzepatide, addressing its structure and function, relationship to current GLP1 receptor agonists, impact of recent results for the treatment and prevention of kidney disease, and expectations for the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto Universitario CEMIC, Buenos Aires, Argentina.
- Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
- RICORS2040, Madrid, Spain.
- Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institue of Research, Barcelona, Spain.
- Geendiab (Diabetic Nephropathy working group of the Spanish Society of Nephrology, Sociedad Española de Nefrologia ).
- Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
ORCID-Profile: María José Soler, Alberto Ortiz, Beatriz Fernandez-Fernandez
Förderung
- FEDER
- PERSTIGAN
- ISCIII-RETIC
- Sociedad Española de Nefrología
- Sociedad Madrileña de Nefrología
- FRIAT
- Comunidad de Madrid en Biomedicina
- Instituto de Salud Carlos III
Zitieren
APA
Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2023). Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal, 16(5), 797-808. https://doi.org/10.1093/ckj/sfac274
Vancouver
Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernandez-Fernandez B. Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal. 2023;16(5):797-808. doi:10.1093/ckj/sfac274
BibTeX
@article{Bosch2023,
author = {Bosch, Catalina and Carriazo, Sol and Soler, María José and Ortiz, Alberto and Fernandez-Fernandez, Beatriz},
title = {Tirzepatide and prevention of chronic kidney disease},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {5},
pages = {797--808},
doi = {10.1093/ckj/sfac274}
}
EUVIMED